Daniel Drucker [Biomarker April 2023] Can GLP-1/GIP therapies improve long term health outcomes
May 2024 data from KFF showed that 6% of adults currently take any GLP-1 drug, with 12% saying they have taken the medications at any point in time
In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study ( With these points in mind, we undertook a broad assessment of published clinical data, curating the body weight loss (% from baseline), glycosylated hemoglobin levels (HbA1c), and nausea responses (% patients reporting) from the SUSTAIN 3, SUSTAIN 7, SCALE Diabetes, SURPASS 2, and STEP 2 trials ( Figures 1AC )
I even threatened to file complaints against their professional licenses, and it didnt trigger anything, he says, his voice peaking as he recounts his experience
It helps curb hunger and creates a feeling of fullness with smaller portions, making it easier to maintain a calorie deficit and achieve weight loss
![Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases](https://ars.els-cdn.com/content/image/1-s2.0-S0001731023008505-fx1.jpg)
